Autism - A Pipeline Analysis Report 2018 | Technavio
LONDON--(BUSINESS WIRE)--Jul 11, 2018--Technavio has announced its pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat autism.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180711005662/en/
Technavio has published a new report on the drug development pipeline for autism, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
Autism: Market overview
Autism or autism spectrum disorder (ASD) is a developmental disability that majorly affects the social interaction and communication of an individual. It is a combination of genetic and environmental factors that challenge an individual’s verbal skills and ability to respond. The major symptom of autism is repetitive behavior that affects information processing in the brain by altering nerve cells.
According to a senior market research analyst at Technavio , “Autism is a neurodevelopmental disorder that is discovered during infancy and childhood. It is characterized by multiple impairments such as reduced eye contact, restricted interests, difficulties in communication, and repetitive behavior. Autism makes it difficult for autistic children to express themselves either through words, gestures, or common facial expressions.”
Autism: Segmentation analysis
This market research report segments the autism market based on therapies employed (monotherapy and unknown), RoA (oral, intranasal, IV, transdermal, transnasal, topical, and unknown), therapeutic modalities (small molecules, microbiome, stem cell, polyclonal antibody, peptide, protein, enzyme, and unknown), targets for drugs under development (GABA receptor, AMPA receptor, mGlu receptor, ADNP, cannabinoid receptor, chymotrypsin, dopamine-2 receptor, LPS, NMDA receptor, Nrf2 and NF-kB, oxytocin receptor, vasopressin receptor 1A, and unknown), and recruitment status (recruiting, active not recruiting, completed, not yet recruiting, and unknown).
Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, around 11 molecules that are being investigated for the treatment of autism are monotherapy.
In case of oral RoA, the delivery of the drug substances is done through the mouth cavity. About 13 molecules that are in the current pipeline are expected to be administered orally.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age Recruitment volume
Key CompaniesType of players Company Overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180711005662/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA SOUTH AMERICA AFRICA MIDDLE EAST
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL PROFESSIONAL SERVICES OTHER PROFESSIONAL SERVICES RESEARCH SCIENCE
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/11/2018 12:55 PM/DISC: 07/11/2018 12:55 PM